Skip to main content
31, Oct 2022

Plexision Aims to Deliver Single-Day Results for Organ Transplant Rejection Testing With Antigen Dx

NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an ant

Read more
23, Oct 2022

PlexAPRTM six hour blood test to predict transplant rejection

Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant pati

Read more
23, Oct 2022

Plexision launches personalized transplant diagnostic testing in India

Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference

Read more
23, Oct 2022

Rapid six-hour test panel to predict CMV infection and transplant rejection

Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegal

Read more
28, Feb 2021

COVID-19 Update: The first non-mRNA vaccine
  • On February 27, the FDA issued an Emergency Use Authorization for Johnson and Johnson’s non-mRNA vaccine.
Read more
13, Dec 2020

The first COVID-19 Vaccine: Trial Results, Regulatory Review, Distribution

Results of Phase 2/3 Clinical Trial:

Read more
17, Oct 2020

WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect

WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect on Mortality, Seve

Read more
15, Nov 2016

Predicting Cytomegalovirus Viremia… With CMV-Specific T-cells

Predicting cytomegalovirus viremia after liver or intestine transplantation (LTx, ITx) with CMV-specific T-cell subse

Read more
15, Nov 2016

Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children

Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation

Read more
Subscribe to News

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact